Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01565655 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis
A Phase 2 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 289
- Enrollment target
NCT01565655 is a Phase 2 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 289 participants.
The verdict
NCT01565655, a Phase 2 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 289 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe rheumatoid arthritis (RA) subjects
Interventions
- DRUG Placebo
- DRUG peficitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 289 participants |
| Start Date | 2012-06-19 |
| Est. Completion | 2013-12-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01565655
The ClinicalTrials.gov registry entry for NCT01565655 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 289 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01565655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01565655 about?
NCT01565655 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis". The purpose of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe rheumatoid arthritis (RA) subjects
What is the current status of trial NCT01565655?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 289 participants. The study started on 2012-06-19. Estimated completion is 2013-12-02.
What interventions are being tested in trial NCT01565655?
The interventions under investigation include: Placebo (DRUG), peficitinib (DRUG).
Who is sponsoring clinical trial NCT01565655?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.